Author:
Lengfelder E, ,Haferlach C,Saussele S,Haferlach T,Schultheis B,Schnittger S,Ludwig W-D,Staib P,Aul C,Grüneisen A,Kern W,Reichle A,Serve H,Berdel W E,Braess J,Spiekermann K,Wörmann B,Sauerland M-C,Heinecke A,Hiddemann W,Hehlmann R,Büchner T
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference36 articles.
1. Estey E, Thall S, Pierce S, Kantarjian H, Keating M . Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483–490.
2. Sanz M, Montesinos P, Vellenga E, Rayón C, de la Serna J, Parody R et al. Risk-adapted therapy of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Blood 2008; 112: 3130–3134.
3. Sanz M, Grimwade D, Tallman M, Lowenberg B, Fenaux P, Estey E et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875–1891.
4. Sanz MA, Lo-Coco F, Martin G, Avvisati G, Rayón C, Barbui T et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247–1252.
5. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone A . Presenting white blood cell counts and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial. Blood 1999; 93: 4131–4143.
Cited by
93 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献